Gutiérrez-Chamorro, Lucía
Felip, Eudald
Castellà, Eva
Quiroga, Vanessa
Ezeonwumelu, Ifeanyi Jude
Angelats, Laura
Esteve, Anna
Perez-Roca, Laia
Martínez-Cardús, Anna
Fernandez, Pedro Luis
Ferrando-Díez, Angelica
Pous, Anna
Bergamino, Milana
Cirauqui, Beatriz
Romeo, Marga
Teruel, Iris
Mesia, Ricard
Clotet, Bonaventura
Riveira-Muñoz, Eva
Margelí, Mireia
Ballana, Ester
Funding for this research was provided by:
Generalitat de Catalunya (2019 FI-B00420)
Instituto de Salud Carlos III (PI17/00624; PI21/00642; CM20/00027; MSII19/00012, PI17/00624; PI21/00642; CM20/00027; MSII19/00012, PI17/00624; PI21/00642; CM20/00027; MSII19/00012)
“la Caixa” Foundation (LCF/BQ/IN18/11660017)
Article History
Accepted: 7 August 2023
First Online: 4 September 2023
Declarations
:
: The study was conducted in accordance with the ethics principles of the Declaration of Helsinki and approved by the Research and Ethics Committee of Hospital Germans Trias i Pujol. Samples were obtained from the Biobank of the Institut d’Investigació Germans Trias i Pujol. All patients provided written informed consent.
: Eudald Felip reports honoraria received from Novartis as advisor and travel expenses from Novartis, Pfizer and Lilly. Vanessa Quiroga reports honoraria received from Novartis and Roche as advisory role or speaker and travel or inscription expenses from GSK, Lilly and Roche. Angelica Ferrando-Díez declares speaking fees from MSD and travel expenses from MSD, Lilly, Roche and Merck. Anna Pous reports travel expenses from Lilly and Roche. Milana Bergamino reports honoraria received from Eisai as advisory role and a patent filed for novel molecular sub-groups within ER + /HER2 + early breast cancer. Beatriz Cirauqui reports honoraria received from BMS, MSD and Merck as invited speaker; and training grants from BMS and MSD. Marga Romeo reports honoraria received from GSK and MSD as advisor; speaker’s bureau from AZ; and research funding from Clovis, AZ, GSK, MSD. Ricard Mesia reports honoraria received from Merck, Nanobiotics, MSD, Seattle Genetics, AZ, Pfizer, Bayer, Boehringer as advisory role and Merck, MSD and Boehringer as speaker. Mireia Margelí reports honoraria received from Novartis, Pfizer, Lilly, Gilead, Piere Fabre and MSD as advisor role or consulting, research funding from Pfizer and travel expenses from Pfizer and Gilead. All other authors declare no conflicts of interest (Lucia Gutiérrez- Chamorro, Eva Castellà, Ifeanyi Jude Ezeonwumelu, Laura Angelats, Anna Esteve, Laia Pérez-Roca, Anna Martínez- Cardús, Pedro Luis Fernández, Iris Teruel, Bonaventura Clotet, Eva Riveira-Muñoz, and Ester Ballana).